BR112015009883A2 - Novas moléculas imunoterapêuticas e os usos das mesmas - Google Patents

Novas moléculas imunoterapêuticas e os usos das mesmas

Info

Publication number
BR112015009883A2
BR112015009883A2 BR112015009883A BR112015009883A BR112015009883A2 BR 112015009883 A2 BR112015009883 A2 BR 112015009883A2 BR 112015009883 A BR112015009883 A BR 112015009883A BR 112015009883 A BR112015009883 A BR 112015009883A BR 112015009883 A2 BR112015009883 A2 BR 112015009883A2
Authority
BR
Brazil
Prior art keywords
molecules
allergy
ara
subjects
new immunotherapeutic
Prior art date
Application number
BR112015009883A
Other languages
English (en)
Inventor
O'hehir Robyn
Rolland Jennifer
Prickett Sara
Original Assignee
Univ Monash
Alfred Health
Aravax Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904780A external-priority patent/AU2012904780A0/en
Application filed by Univ Monash, Alfred Health, Aravax Pty Ltd filed Critical Univ Monash
Publication of BR112015009883A2 publication Critical patent/BR112015009883A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

NOVAS MOLÉCULAS IMUNOTERAPÊUTICAS E OS USOS DAS MESMAS. Esta invenção se relaciona geralmente às moléculas tais como peptídeos, polipeptídeos e proteínas que interagem imunologicamente com os linfócitos T em sujeitos que têm alergia aos amendoins, ou alergia a outras nozes, e seqüências genéticas que codificam os mesmos. Estas moléculas são de preferência imunointerativas com as células T nos sujeitos que têm alergia ao alérgeno Ara h 1. As moléculas desta invenção são úteis no desenvolvimento de agentes diagnósticos, terapêuticos e profilático para as condições caracterizadas por uma resposta imune aberrante, inadequada ou de outro modo indesejada à Ara h 1 ou derivado ou homólogo dos mesmos.
BR112015009883A 2012-10-30 2013-10-30 Novas moléculas imunoterapêuticas e os usos das mesmas BR112015009883A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012904780A AU2012904780A0 (en) 2012-10-30 Novel immunotherapeutic molecules and uses thereof
PCT/AU2013/001255 WO2014066939A1 (en) 2012-10-30 2013-10-30 Novel immunotherapeutic molecules and uses thereof

Publications (1)

Publication Number Publication Date
BR112015009883A2 true BR112015009883A2 (pt) 2017-08-22

Family

ID=50626213

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009883A BR112015009883A2 (pt) 2012-10-30 2013-10-30 Novas moléculas imunoterapêuticas e os usos das mesmas

Country Status (16)

Country Link
US (2) US11096994B2 (pt)
EP (2) EP3964232A1 (pt)
JP (3) JP6608282B2 (pt)
KR (1) KR102135732B1 (pt)
CN (2) CN110075285A (pt)
AU (3) AU2013337596B2 (pt)
BR (1) BR112015009883A2 (pt)
CA (2) CA3177836A1 (pt)
DK (1) DK2914286T3 (pt)
ES (1) ES2897421T3 (pt)
MX (2) MX2015005636A (pt)
NZ (1) NZ707615A (pt)
PL (1) PL2914286T3 (pt)
RU (1) RU2687164C2 (pt)
WO (1) WO2014066939A1 (pt)
ZA (1) ZA201503542B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2687164C2 (ru) 2012-10-30 2019-05-07 Аравакс Пти Лтд Новые иммунотерапевтические молекулы и их применения
BR112016006813A2 (pt) 2013-09-25 2017-09-19 Aravax Pty Ltd Composição imunoterapêutica nova e seus usos
FR3062797A1 (fr) * 2017-02-10 2018-08-17 Centre Hospitalier Et Universitaire De Clermont-Ferrand Gelule a liberation gastro-intestinale destinee a etre utilisee dans une methode permettant de desensibiliser et/ou d'induire une tolerance chez un sujet allergique a l'arachide
WO2020237181A1 (en) * 2019-05-23 2020-11-26 Aimmune Therapeutics, Inc. Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558869A (en) 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
JPH11507840A (ja) 1995-12-29 1999-07-13 ユニバーシティ オブ アーカンソー ピーナッツアレルゲンおよび方法
US20030202980A1 (en) 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US6835824B1 (en) * 1995-12-29 2004-12-28 University Of Arkansas Peanut allergens and methods
WO1999034826A1 (en) 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
CA2318493A1 (en) 1998-01-16 1999-07-22 The Johns Hopkins University Oral delivery of nucleic acid vaccines by particulate complexes
DE69940805D1 (de) 1998-01-31 2009-06-10 Sinai School Medicine Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
AU3085299A (en) 1998-03-12 1999-09-27 Board Of Trustees Of The University Of Arkansas, The Tertiary structure of peanut allergen ara h 1
WO2000052154A2 (en) 1999-03-02 2000-09-08 The Board Of Trustees Of The University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
AU3865400A (en) 1999-03-03 2000-09-21 Mount Sinai School Of Medicine Of The City University Of New York, The Animal model of allergies
WO2000054803A2 (en) 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
WO2001040264A2 (en) 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Peptide antigens
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
KR100919914B1 (ko) 2000-11-16 2009-10-06 알크-아벨로 에이/에스 신규한 돌연변이체 알레르겐
RU2285042C2 (ru) 2000-11-16 2006-10-10 Альк-Абелло А/С Новые мутантные аллергены
WO2002074250A2 (en) 2001-03-16 2002-09-26 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002088317A2 (en) 2001-05-01 2002-11-07 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
DE60229979D1 (pt) 2001-12-05 2009-01-02 Circassia Ltd
CA2499123A1 (en) * 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-key/antigenic epitope hybrid peptide vaccines
US7179645B2 (en) 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US7923209B2 (en) * 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
US8057800B2 (en) 2004-06-10 2011-11-15 Circassia Limited Immunointeractive molecules and uses thereof
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
AU2007240964A1 (en) * 2006-03-30 2007-11-01 The Regents Of The University Of California IgE directed DNA vaccination
FI20075063A0 (fi) 2007-02-01 2007-02-01 Vactech Oy Allergisen herkistymisen estäminen
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
SI2083856T1 (sl) 2007-08-15 2011-02-28 Circassia Ltd Peptidi za desenzibilizacijo proti alergijam
GB2455108A (en) 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
EP2140880B1 (en) 2008-07-04 2012-11-14 HAL Allergy Holding B.V. Modification of allergens
EP2153841B2 (en) 2008-08-15 2015-11-11 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
WO2010018384A1 (en) 2008-08-15 2010-02-18 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
WO2011032097A1 (en) * 2009-09-14 2011-03-17 Mount Sinai School Of Medicine Methods for characterizing antibody binding affinity and epitope diversity in food allergy
US20130004528A1 (en) * 2010-02-26 2013-01-03 Benaroya Research Institute Direct analysis of antigen-specific immune response
US8835361B2 (en) 2010-06-01 2014-09-16 The Curators Of The University Of Missouri High-throughput quantitation of crop seed proteins
US9517257B2 (en) * 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
GB201104537D0 (en) * 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
WO2012129246A2 (en) 2011-03-20 2012-09-27 The Regents Of The University Of Colorado, A Body Corporate Method for predicting severity of allergic reaction
US9289477B2 (en) 2011-04-29 2016-03-22 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
JP2013040138A (ja) 2011-08-17 2013-02-28 Univ Of Tsukuba 活性化型リコンビナント花粉アレルゲンの作製方法
WO2013036293A1 (en) 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Dendritic cell subsets for generating induced tolerogenic dendritic cells and related compositions and methods
CN102533781B (zh) 2011-12-30 2013-09-11 华南师范大学 花生2s-4b蛋白在诱导细胞凋亡中的应用
CN102816232B (zh) 2011-12-30 2014-07-16 华南师范大学 花生2s-4b蛋白及其生产方法
PL2802607T3 (pl) 2012-01-13 2018-03-30 Julius-Maximilians-Universität Würzburg Dwuskładnikowa komplementacja funkcjonalna wywoływana przez podwójny antygen
BR112014031327B1 (pt) 2012-06-15 2022-02-01 Immunomic Therapeutics, Inc Moléculas de ácido nucleico para o tratamento de alergias
RU2687164C2 (ru) 2012-10-30 2019-05-07 Аравакс Пти Лтд Новые иммунотерапевтические молекулы и их применения
WO2014067993A1 (en) 2012-11-01 2014-05-08 Veterinærinstituttet New fusion proteins for the treatment of allergic diseases
CN105163756A (zh) 2013-03-15 2015-12-16 赛门蒂斯有限公司 免疫调节
BR112016006813A2 (pt) 2013-09-25 2017-09-19 Aravax Pty Ltd Composição imunoterapêutica nova e seus usos

Also Published As

Publication number Publication date
PL2914286T3 (pl) 2022-01-31
AU2017261619B2 (en) 2019-07-04
US20220088159A1 (en) 2022-03-24
MX2020012569A (es) 2021-02-18
US11096994B2 (en) 2021-08-24
JP2021185162A (ja) 2021-12-09
WO2014066939A1 (en) 2014-05-08
EP3964232A1 (en) 2022-03-09
ES2897421T3 (es) 2022-03-01
AU2019240574B2 (en) 2021-12-09
JP6608282B2 (ja) 2019-11-20
JP2015533837A (ja) 2015-11-26
CN110075285A (zh) 2019-08-02
US11980658B2 (en) 2024-05-14
KR20150110472A (ko) 2015-10-02
RU2687164C2 (ru) 2019-05-07
AU2013337596B2 (en) 2017-08-31
JP2018184447A (ja) 2018-11-22
CA2889784C (en) 2024-04-30
NZ707615A (en) 2019-01-25
CA3177836A1 (en) 2014-05-08
DK2914286T3 (da) 2021-11-08
KR102135732B1 (ko) 2020-07-21
CN105120894A (zh) 2015-12-02
RU2015120543A (ru) 2016-12-20
CN105120894B (zh) 2019-02-15
AU2019240574A1 (en) 2019-10-24
CA2889784A1 (en) 2014-05-08
EP2914286A4 (en) 2016-06-01
ZA201503542B (en) 2023-12-20
US20150328294A1 (en) 2015-11-19
AU2013337596A1 (en) 2015-05-21
EP2914286B1 (en) 2021-08-18
EP2914286A1 (en) 2015-09-09
MX2015005636A (es) 2015-11-16
AU2017261619A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
PE20151673A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BR112019001099A2 (pt) usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc
BR112015009883A2 (pt) Novas moléculas imunoterapêuticas e os usos das mesmas
PE20151763A1 (es) Muteinas de interleucina-2 para la expansion de celulas t reguladoras
BR112019010972A2 (pt) receptores de células t e imunoterapia usando os mesmos
BR112017008525A2 (pt) proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo.
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
BRPI0806578A8 (pt) Promotores de lactococcus e usos dos mesmos
BR112017016336A2 (pt) proteínas de ligação icos agonistas?
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
BR112017016705A2 (pt) agentes de ligação a tnfrsf e uso dos mesmos
BR112017020961A2 (pt) muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
BR112017018975A2 (pt) proteínas de fusão compreendendo uma proteína de ligação e um polipeptídeo de interleucina-15 tendo uma afinidade reduzida com il15ra e usos terapêuticos das mesmas
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
BR112014010161A2 (pt) anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
BR112012027055A8 (pt) agente estabilizante para proteínas farmacêuticas.
BR112014019459A8 (pt) Proteínas de ligação à cdim e usos das mesmas
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
BR112014031327A2 (pt) ácidos nucleicos para o tratamento de alergias
BR112016027595A8 (pt) produtos de peptídeos, composição farmacêutica compreendendo um produto de peptídeo, uso de um produto de peptídeo e método para produzir um produto de peptídeo
BRPI1014016B8 (pt) anticorpos humanizados para receptor tipo toll 2 e usos dos mesmos.
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
BR112014023642A2 (pt) proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ARAVAX PTY LTD (AU)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.